Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) just unveiled an announcement.
Jiangsu Recbio Technology reported audited annual results for 2025 alongside an update on its advancing vaccine pipeline, underscoring its positioning in high-value prophylactic markets. The company is progressing late-stage candidates targeting shingles and HPV, aiming to capture demand in China and expand into key overseas regions.
The company completed full-course vaccination and a large-scale Phase III-style clinical study for its novel adjuvanted recombinant shingles vaccine REC610 in adults aged 40 and above, enrolling 24,640 subjects across three Chinese provinces. A clinical summary was obtained and a marketing application for REC610 was submitted and accepted in December 2025, marking a pivotal step toward potential commercialization.
For its recombinant HPV 9-valent vaccine REC603, Recbio initiated the 54th-month follow-up after full immunization as part of long-term efficacy and safety monitoring. 2025 also marked a breakthrough year for the HPV franchise internationally, with the company signing development, registration and commercialization agreements with leading partners in India and Russia and already recognizing some related revenue, highlighting growing global commercial traction.
The most recent analyst rating on (HK:2179) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a China-based biopharmaceutical company focused on vaccine research and development, particularly in recombinant and adjuvanted vaccines. Its pipeline targets major infectious diseases, including shingles and human papillomavirus, with an eye on both domestic and international vaccine markets.
Average Trading Volume: 68,161
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.22B
Find detailed analytics on 2179 stock on TipRanks’ Stock Analysis page.